Latest in News & Research

Difelikefalin Improves Itch Intensity in Notalgia Paresthetica

However, more frequent headache, dizziness, constipation, increased urine output seen for patients receiving difelikefalin versus placebo

By Elana Gotkine (HealthDay News) | | February 09, 2023

Is Collagenase Clostridium Histolyticum-aaes Effective for Thigh Cellulite?

CCH-aaes found to be effective and well tolerated for thigh cellulite, with reduction seen in patient-reported bother due to cellulite

By Dermsquared Editorial Team | | February 08, 2023

Morphea Activity Measure Reliable, Valid for Disease Activity

Moderately strong correlations seen between MAM and modified Localized Scleroderma Severity Index, Physician Global Assessment of Activity

By Dermsquared Editorial Team | | February 08, 2023

Measles Outbreak in Ohio Declared Over After 85 Cases

Outbreak declared finished with no new cases after a period of 42 days, or the equivalent of two measles virus incubation periods

By Physician's Briefing Staff | | February 06, 2023

Is Dupilumab Beneficial for Treatment of Erythrodermic Atopic Dermatitis?

Significant improvements reported in percentage BSA affected by AD, Eczema Area and Severity Index score, Peak Pruritus Numerical Rating Scale score

By Dermsquared Editorial Team | | February 01, 2023

Local Recurrence Rate Low With Mohs for Invasive Head, Neck Melanoma

Disease-specific survival was 96.8 and 93.4 percent at five and 10 years, respectively

By Dermsquared Editorial Team | | February 01, 2023

CDC Reports on Prevalence of Seasonal and Food Allergies, Eczema

18.9 percent of children and 25.7 percent of adults had seasonal allergy; 10.8 and 7.3 percent had eczema in 2021

By Elana Gotkine (HealthDay News) | | January 26, 2023

What Is the Prevalence of Depression, Anxiety Disorders in Alopecia Areata Patients?

Prevalence of depression disorder 9 percent, anxiety disorder 7 to 17 percent; prevalence of disorders lower than depression and anxiety symptom prevalence

By Dermsquared Editorial Team | | January 25, 2023

Guidelines Issued for Gene Expression Profiling in Cutaneous Melanoma

GEP results can improve prognostic assessment for patients with tumors with uncertainty about adequacy of microstaging

By Dermsquared Editorial Team | | January 25, 2023

Risk for Subsequent Facial Keratinocyte Carcinoma Lower With Laser Treatment

Nonablative fractional laser-treated patients had lower rate of subsequent facial keratinocyte carcinoma development

By Elana Gotkine (HealthDay News) | | January 24, 2023

Air Pollution Tied to Psoriasis Occurrence

Females, children more sensitive to changes in air pollutants

By Lori Solomon (HealthDay News) | | January 23, 2023

Health Concepts From PROMs Can Be Classified Into Five Domains for Psoriasis

Most frequently captured domains are social well-being and psychological well-being; no PROM captured all five domains

By Elana Gotkine (HealthDay News) | | January 23, 2023

Guidelines Updated for Topical Treatment of Atopic Dermatitis in Adults

Strong recommendations include use of moisturizers, topical corticosteroids, topical calcineurin inhibitors

By Dermsquared Editorial Team | | January 18, 2023

Rates of Clinic Visits for Psoriasis Increased for Adults After Wildfires

Air pollution from wildfire linked to modestly increased rates of clinic visits for psoriasis among adults starting five weeks after fire

By Dermsquared Editorial Team | | January 18, 2023

MPATH-Dx Version 2.0 Simplifies Classification of Melanoma

Updated version simplifies original five-class hierarchy into four classes, including clearly defining classes I and II lesions

By Elana Gotkine (HealthDay News) | | January 13, 2023

Do Outcomes Improve With Lebrikizumab in Atopic Dermatitis?

Improvement seen in IGA(0,1) and in EASI-75 with lebrikizumab plus topical corticosteroids versus placebo plus topical corticosteroids

By Dermsquared Editorial Team | | January 11, 2023

Risankizumab Safe, Effective at 52 Weeks for Psoriatic Arthritis

Long-term benefits seen in patients with inadequate response/intolerance to biologic or conventional disease-modifying antirheumatic drugs

By Lori Solomon (HealthDay News) | | January 11, 2023

Survival Rates High for Children, Teens With Melanoma

Primary tumor ulceration, head/neck location, and Breslow thickness >4 mm predict worse survival in teens

By Lori Solomon (HealthDay News) | | January 10, 2023

Is Melanoma Survival Worse for Adolescents, Young Adults Versus Older Adults

Adolescents and young adults with stage IV melanoma have worse survival than that seen for older adults in adjusted age group-specific models

By Lori Solomon (HealthDay News) | | January 10, 2023

Mpox Cases Reported in Cisgender Women

2.3 percent of all reported mpox cases were in cisgender women, 44 percent of whom were non-Hispanic Black

By Elana Gotkine (HealthDay News) | | January 05, 2023

Can Certain Factors Predict Poor Outcomes in Cutaneous Squamous Cell Carcinoma?

Risks for local recurrence, disease-specific death highest in association with tumor invasion beyond subcutaneous fat

By Dermsquared Editorial Team | | January 04, 2023

Is Risk for SARS-CoV-2 Infection Increased With Biologics in Psoriasis?

Incidence of SARS-CoV-2 infection no higher with biologics, nonbiologic systemics versus other treatments

By Dermsquared Editorial Team | | January 04, 2023

Current Depression Linked to Systemic Inflammation in Psoriasis

Correlation of PHQ-2 scores with neutrophil count greater and significant only for women

By Elana Gotkine (HealthDay News) | | January 04, 2023

24 of 1292

Headline from the Week of October 19 - 25, 2026

The Distance Between Habit and Strategy

By Dermsquared Editorial Team | | October 23, 2026

From Poster to Practice: The Control Gap in CIndU

| October 23, 2026